(NASDAQ: RXRX) Recursion Pharmaceuticals's forecast annual revenue growth rate of 23.96% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.29%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.03%.
Recursion Pharmaceuticals's revenue in 2024 is $44,575,000.On average, 5 Wall Street analysts forecast RXRX's revenue for 2024 to be $10,734,917,887, with the lowest RXRX revenue forecast at $1,579,920,480, and the highest RXRX revenue forecast at $19,546,617,558. On average, 5 Wall Street analysts forecast RXRX's revenue for 2025 to be $12,970,694,263, with the lowest RXRX revenue forecast at $2,996,522,283, and the highest RXRX revenue forecast at $20,555,626,627.
In 2026, RXRX is forecast to generate $26,833,540,266 in revenue, with the lowest revenue forecast at $4,765,573,301 and the highest revenue forecast at $48,901,741,885.